xCT与肿瘤和肿瘤干细胞关系的研究进展

doi:10.13481/j.1671-587x.20190646

[1] KOPPULA P, ZHANG Y, ZHUANG L, et al. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer[J]. Cancer Commun (Lond), 2018, 38(1): 12.
[2] LEWERENZ J, HEWETT S J, HUANG Y, et al. The Cystine/Glutamate antiporter system xc^- in health and disease: From molecular mechanisms to novel therapeutic opportunities[J]. Antioxid Redox Sign, 2013, 18(5): 522-555.
[3] LIM J C, DONALDSON P J. Focus on molecules: The cystine/glutamate exchanger (System x(c)(-))[J]. Exp Eye Res, 2011, 92(3): 162-163.
[4] SHIN C S, MISHRA P, WATROUS J D, et al. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility[J]. Nat Commun, 2017, 8: 15074.
[5] CHEN D, TAVANA O, CHU B, et al. NRF2 is a major target of ARF in p53-Independent tumor suppression[J]. Mol Cell, 2017, 68(1): 224-232.
[6] LEWERENZ J, MAHER P. Basal levels of eIF2alpha phosphorylation determine cellular antioxidant status by regulating ATF4 and xCT expression[J]. J Biol Chem, 2009, 284(2): 1106-1115.
[7] CLEMONS N J, LIU D S, DUONG C P, et al. Inhibiting system xC(-) and glutathione biosynthesis-a potential Achilles’ heel in mutant-p53 cancers[J]. Mol Cell Oncol, 2017, 4(5): e1344757.
[8] YANG Y, YEE D. IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC[J]. Cancer Res, 2014, 74(8): 2295-2305.
[9] WANG X, LI Y, WANG H, et al. Propofol inhibits invasion and proliferation of C6 glioma cells by regulating the Ca²⁺ permeable AMPA receptor-system x c^- pathway[J]. Toxicol in Vitro, 2017, 44: 57-65.
[10] PAKOS-ZEBRUCKA K, KORYGA I, MNICH K, et al. The integrated stress response[J]. Embo Rep, 2016, 17(10): 1374-1395.
[11] YE P, MIMURA J, OKADA T, et al. Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of t24 bladder carcinoma cells to proteasome inhibition[J]. Mol Cell Biol, 2014, 34(18): 3421-3434.
[12] MARTIN L, GARDNER L B. Stress-induced inhibition of nonsense-mediated RNA decay regulates intracellular cystine transport and intracellular glutathione through regulation of the cystine/glutamate exchanger SLC7A11[J]. Oncogene, 2015, 34(32): 4211-4218.
[13] DRAYTON R M, DUDZIEC E, PETER S, et al. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11[J]. Clin Cancer Res, 2014, 20(7): 1990-2000.
[14] LIU X X, LI X J, ZHANG B, et al. MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11[J]. Febs Lett, 2011, 585(9): 1363-1367.
[15] WU Y, SUN X, SONG B, et al. MiR-375/SLC7A11 axis regulates oral squamous cell carcinoma proliferation and invasion[J]. Cancer Med, 2017, 6(7): 1686-1697.
[16] ISHIMOTO T, NAGANO O, YAE T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc^- and thereby promotes tumor growth[J]. Cancer Cell, 2011, 19(3): 387-400.
[17] GU Y, ALBUQUERQUE C P, BRAAS D, et al. MTORC2 regulates amino acid metabolism in cancer by phosphorylation of the Cystine-Glutamate antiporter xCT[J]. Mol Cell, 2017, 67(1): 128-138.
[18] JI X, QIAN J, RAHMAN S, et al. XCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression[J]. Oncogene, 2018, 37(36): 5007-5019.
[19] ZHONG W, WEISS H L, JAYSWAL R D, et al. Extracellular redox state shift: A novel approach to target prostate cancer invasion[J]. Free Radical Bio Med, 2018, 117: 99-109.
[20] 郑雪婷,赵飞,赵瑞,等. xCT调节乳腺癌细胞转移的作用机制研究[J]. 军事医学,2015(5): 334-338.
[21] 李杨,齐建利,赵立平,等. xCT影响肝癌细胞转移的作用机制研究[J]. 天津医科大学学报,2014(2): 93-97.
[22] KINOSHITA H, OKABE H, BEPPU T, et al. Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma[J]. Oncol Rep, 2013, 29(2): 685-689.
[23] MA Z, ZHANG H, LIAN M, et al. SLC7A11, a component of cysteine/glutamate transporter, is a novel biomarker for the diagnosis and prognosis in laryngeal squamous cell carcinoma[J]. 2017, 38(5): 3019-3029.
[24] LEE J R, ROH J L, LEE S M, et al. Overexpression of cysteine-glutamate transporter and CD44 for prediction of recurrence and survival in patients with oral cavity squamous cell carcinoma[J]. Head Neck, 2018.DOI:10.1002/hed.25331
[25] OTSUBO K, NOSAKI K, IMAMURA C K, et al. Phase Ⅰ study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer[J]. Cancer Sci, 2017, 108(9): 1843-1849.
[26] POLEWSKI M D, REVERON-THORNTON R F, CHERRYHOLMES G A, et al. Increased expression of system xc^- in glioblastoma confers an altered metabolic state and temozolomide resistance[J]. Mol Cancer Res, 2016, 14(12): 1229-1242.
[27] MAUGERI-SACCA M, VIGNERI P, De MARIA R. Cancer stem cells and chemosensitivity[J]. Clin Cancer Res, 2011, 17(15): 4942-4947.
[28] YE X Q, LI Q, WANG G H, et al. Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells[J]. Int J Cancer, 2011, 129(4): 820-831.
[29] POLEWSKI M D, REVERON-THORNTON R F, CHERRYHOLMES G A, et al. SLC7A11 overexpression in glioblastoma is associated with increased cancer stem cell-like properties[J]. Stem Cells Dev, 2017, 26(17): 1236-1246.
[30] THANEE M, LOILOME W, TECHASEN A, et al. CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment[J]. Cancer Sci, 2016, 107(7): 991-1000.
[31] SHITARA K, DOI T, NAGANO O, et al. Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)[J]. Gastric Cancer, 2017, 20(6): 1004-1009.
[32] OTSUBO K, NOSAKI K, IMAMURA C K, et al. Phase Ⅰ study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer[J]. Cancer Sci, 2017, 108(9): 1843-1849.
[33] TAKAYAMA T, KUBO T, MORIKAWA A, et al. Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer[J]. Med Oncol, 2016, 33(5): 45.
[34] LU H, SAMANTA D, XIANG L, et al. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype[J]. Proc Natl Acad Sci U S A, 2015, 112(33): E4600-E4609.
[35] KOGLIN N, MUELLER A, BERNDT M, et al. Specific PET imaging of xC-transporter activity using a (1)(8)F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism[J]. Clin Cancer Res, 2011, 17(18): 6000-6011.
[36] BAEK S, MUELLER A, LIM Y S, et al. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: Preclinical and exploratory clinical studies[J]. J Nucl Med, 2013, 54(1): 117-123.
[37] KAVANAUGH G, WILLIAMS J, MORRIS A S, et al. Utility of ¹⁸F-FSPG PET to image hepatocellular carcinoma: First clinical evaluation in a US population[J]. Mol Imaging Biol, 2016, 18(6): 924-934.
[38] MITTRA E S, KOGLIN N, MOSCI C, et al. Pilot preclinical and clinical evaluation of (4S)-4-(3-[18F]fluoropropyl)-L-Glutamate (¹⁸F-FSPG) for PET/CT imaging of intracranial malignancies[J]. PLoS One, 2016, 11(2): e148628.
[39] BAEK S, CHOI C M, AHN S H, et al. Exploratory clinical trial of (4S)-4-(3-¹⁸F fluoropropyl)-L-glutamate for imaging xC-transporter using positron emission tomography in patients with Non-Small cell lung or breast cancer[J]. Clin Cancer Res, 2012, 18(19): 5427-5437.
[40] MA M Z, CHEN G, WANG P, et al. Xc-inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism[J]. Cancer Lett, 2015, 368(1): 88-96.
[41] LO M, LING V, LOW C, et al. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer[J]. Curr Oncol, 2010, 17(3): 9-16.
[42] SONG Y, JANG J, SHIN T H, et al. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells[J]. J Exp Clin Cancer Res, 2017, 36(1): 38.
[43] HARYU S, SAITO R, JIA W, et al. Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model[J]. J Neurooncol, 2018, 136(1): 23-31.
[44] RODMAN S N, SPENCE J M, RONNFELDT T J, et al. Enhancement of radiation response in breast cancer stem cells by inhibition of thioredoxin- and Glutathione-Dependent metabolism[J]. Radiat Res, 2016, 186(4): 385-395.
[45] SEISHIMA R, OKABAYASHI K, NAGANO O, et al. Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(+) cancer stem cells in ulcerative colitis-related cancer[J]. Clin Res Hepatol Gastroenterol, 2016, 40(4): 487-493.

Research progress in relationship between xCT and cancer and cancer stem cells

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	YANG Zhiyuan, WEN Naiyan, LIN Yang, LIANG Hang, WANG Qian, HU Xindan, ZHANG Ling, REN Hui, GUO Baofeng. Inhibitory effect of SF2523 on proliferation of human glioma stem cells TS576 and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2019, 45(06): 1281-1287.
[2]	. Research progress in role of human bone marrow stromal antigen-2 in occurrence and development of tumor [J]. Journal of Jilin University(Medicine Edition), 2019, 45(04): 976-980.
[3]	. Research progress in generation and biological functions of exosome [J]. Journal of Jilin University(Medicine Edition), 2018, 44(05): 1109-1114.
[4]	ZHANG Yanxia, LI Yuehui, ZHANG Lihong, ZHANG Nianping, YAN Yanyan, YANG Xiaohui, FENG Xiangling. Effects of silencing HOXA13 gene on malignant phenotypes of hepatocellular carcinoma HepG₂ and QGY-7703 cells [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 315-320.
[5]	CAO Rangjuan, LI Kai, XING Wanying, WANG Yueshu, YU Wei, WU Guangzhi, CUI Shusen, LI Qiang. Expression of Disabled-1 in human breast cancer cells and its role in cell cycle [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 932-936.
[6]	YU Zhiyun, LI Yunqian, CHEN Yong, ZHAO Liyan, LIU Huanbing, WANG Nan, WANG Bin, CHEN Yunzhao, ZHAO Gang. Elimination of temozolomide in combination with metformin on glioma stem cells and its mechanism [J]. Journal of Jilin University Medicine Edition, 2015, 41(02): 321-326.
[7]	WU Min, ZHAO Hongguang, GUAN Feng, SA Ri, LIN Chenghe. Application of ¹⁸F-FDG PET-CT imaging in diagnosis of primary central nervous system lymphoma [J]. Journal of Jilin University Medicine Edition, 2015, 41(02): 401-404.
[8]	YANG Yanyan, JIN Minghua, LI Yanbo, LI Yang, WANG Jiahui, ZHENG Tong, WANG Sihui, CHI Xiangyu, ZHANG Yujia, SUN Zhiwei. Induction effect of nano- SiO₂ on apoptosis of neuroblastoma SH-SY5Y cells and its mechanism [J]. Journal of Jilin University Medicine Edition, 2015, 41(02): 249-254.
[9]	LIU Tong,LI Dan-ni*,LI Yang,LI Feng. Construction and expression of wild type and inactive type of GST-tagged eukaryotic expression vectors of PAK1 gene autoinhibitory domain [J]. Journal of Jilin University Medicine Edition, 2014, 40(01): 27-30.
[10]	SHU Chang，KAN Zhi-sheng，ZHU Yan-bing，CAO Li-ying. Correlation analysis on MRI quantitative parameters and expression level of HIF-1α in cerebral astrocytoma [J]. Journal of Jilin University Medicine Edition, 2013, 39(1): 109-112.
[11]	. Advance research on role of carcinoembryonic antigen-relatedcell adhesion molecule 1 in occurrence, development and metastasis of tumor  [J]. J4, 2012, 38(5): 1037-1042.
[12]	WANG Li-qun\| XU Ye\|JIN Ren-shun. Expressions \|of EGFR and TGF-α \|in prostatic adenocarcinoma and prostatic intraepithelial neoplasia tissues and their clinical significances [J]. J4, 2012, 38(2): 308-311.
[13]	ZHU Dai-hua,WEN You-wu,YANG Han,LIANG Guang-xi. Anti-cancer effect of Hath1 in pathogenesis of non-mucinous colon adenocarcinoma [J]. J4, 2011, 37(4): 700-706.
[14]	WANG Yan,JIANG Hai-yang,YU He,GUAN Chao,JIANG Xue-jun. Detection of expressions of neurofilament and myelin basic protein in acoustic tumor tissues and its significances [J]. J4, 2011, 37(4): 688-690.
[15]	. Role of Fli-1 in tumorigenesis and development [J]. J4, 2011, 37(3): 567-570.